Next Article in Journal
Recent Advances and Future Perspectives of In Vivo Targeted Delivery of Genome-Editing Reagents to Germ cells, Embryos, and Fetuses in Mice
Previous Article in Journal
The Brain–Skin Connection and the Pathogenesis of Psoriasis: A Review with a Focus on the Serotonergic System
Previous Article in Special Issue
NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias
Open AccessReview

The Many Facets of CD38 in Lymphoma: From Tumor–Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy

1
Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, 20089 Milano, Italy
2
Department of Biomedical Sciences, Humanitas University, Rozzano, 20089 Milano, Italy
*
Author to whom correspondence should be addressed.
Cells 2020, 9(4), 802; https://doi.org/10.3390/cells9040802
Received: 13 February 2020 / Revised: 19 March 2020 / Accepted: 25 March 2020 / Published: 26 March 2020
The CD38 antigen is expressed in several hematological malignancies, and the anti-CD38 monoclonal antibodies Daratumumab and Isatuximab have an established role in the therapy of multiple myeloma. However, data on the therapeutic utility of CD38 targeting in other lymphoid malignancies are limited. In chronic lymphocytic leukemia, the prognostic significance of CD38 expression is well accepted, and preclinical studies on the use of Daratumumab in monotherapy or combination therapy have demonstrated considerable efficacy. In other lymphoproliferative disorders, preclinical and clinical data have not been as compelling; however, CD38 overexpression likely contributes to resistance to checkpoint inhibitors, prompting numerous clinical trials in Hodgkin and non-Hodgkin lymphoma to investigate whether blocking CD38 enhances the efficacy of checkpoint inhibitors. Furthermore, due to its widespread expression in hematological tumors, CD38 represents an attractive target for cellular therapies such as CAR-T cells. The present review discusses current knowledge of CD38 expression and its implications in various lymphoid malignancies. Furthermore, it addresses current and future therapeutic perspectives, with a particular emphasis on the significance of CD38 interaction with immune cells of the tumor microenvironment. Lastly, results of ongoing studies using anti-CD38 antibodies will be reviewed. View Full-Text
Keywords: CD38; lymphoma; Daratumumab; immunoescape; checkpoint inhibitors CD38; lymphoma; Daratumumab; immunoescape; checkpoint inhibitors
Show Figures

Figure 1

MDPI and ACS Style

Calabretta, E.; Carlo-Stella, C. The Many Facets of CD38 in Lymphoma: From Tumor–Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy. Cells 2020, 9, 802.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop